Pharma Faces: Shirley Xu, Baxter China
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Address: 20th Floor, NCPC Building (Grand Milea Hotel), No.56 North Tiyu Street, Shijiazhuang, Hebei, P.R.China, Post Code: 050015
Tel: +86 311 85992911
Web: http://www.ncpc.com/
North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC in its early days was one of the key construction projects during the Chinese First Five-Year Plan. After five years of construction beginning in June 1953, operation commenced in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC has a history of commercial production of antibiotics in China. With 45 years of development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking as one of the Top 500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets were USD2 billion, and the company was employing 18500 staff. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of ‘Service for Life ‘, NCPC aims to build bright future for all the people.
Antibiotics, Immunosuppressants
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually…
Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs…
Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the…
The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang,…
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio…
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally.…
PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews,…
Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to…
With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the…
See our Cookie Privacy Policy Here
